SciELO - Scientific Electronic Library Online

vol.38 número1Síndrome serotonínico secundario al uso de paroxetina en una paciente en hemodiálisis periódica índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados



  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO


Revista Cubana de Medicina Militar

versión On-line ISSN 1561-3046


MULET PEREZ, Agustín et al. Acute viral hepatitis C: treatment with high dose of human recombinant alpha 2b interpheron (Heberon alfa R). Rev Cub Med Mil [online]. 2009, vol.38, n.1, pp. 0-0. ISSN 1561-3046.

INTRODUCTION: For the treatment of acute viral hepatitis C, a number of therapeutic regimes with Interferon has been put forward. This paper presented our own experience in the application of a therapy different from the Standard treatment recommended in Cuba, which consisted of the parenteral administration of 3 million doses of recombinant Interferon Alpha 2b three times a week for 6 months. METHODS: The medical records of two patients, who were diagnosed with acute viral hepatitis C on the basis of clinical and epidemiological data, humoral alterations and positive viral markers, were reviewed, using histological diagnosis in one of them. They were administered 5 million Heberon Alpha R subcutaneously for 4 weeks and then additional 5 millions using the same way of administration three times a week to complete 6 months of treatment. RESULTS: Two months after finishing the treatment, the patients remained asymptomatic, gluthamic-piruvic transaminase scores were normal and Virus C RNA proved to be negative after evolving PCR. CONCLUSIONS: The therapy used in these patients proved to be effective, so it is recommended to treat acute viral hepatitis C.

Palabras clave : acute hepatitis C; treatment; recombinant interferon alpha..

        · resumen en Español     · texto en Español     · Español ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License